Cholangiocellular carcinoma

Immunohistochemistry has been used for investigating the expression of HER-2-4 in 38 intrahepatic cholangiocellular carcinomas (Ito et al., 2001). HER-2 expression was observed in more than 50% of the cases but was not related to any clinicopathological features. HER-3 expression was linked to lymph node metastasis, and HER-4 expression was directly related to proliferating activity and lymph node metastasis. 

Ito, Y., Takeda, T., Sasaki, Y., Sakon, M., Yamada, T., Ishiguro, S., Imaoka, S., Tsujimoto, M., Higashiyama, S., Monden, M., and Matsuura, N. 2001. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol. Res. Pract. 197 95-100. 

Tab. 37.11 Diagnostic parameters and examination techniques in cholangiocellular carcinoma...

Angiography CT arteriography, CT arterioportography or MR angiography may help to detect vascular invasion and irregularities. Cholangiocellular carcinomas are poorly vascularized. 

Resection or liver transplantation are considered to be the only curative forms of treatment for cholangiocellular carcinoma. External or intracavitary radiation therapy is the method of choice when it comes to palliative measures. The spectrum of adjuvant or alternative therapy procedures used in HCC is broad, as it is for all oncological conditions. 

Shiraishi, M., Takushi, Y., Simoji, H., Oshiro, T., Shinzato, S., Tani-gawa, N., Kusano, T., Muto, Y. Combined hepatocellular and cholangiocellular carcinoma in a non-cirrhotic liver. J. Gastroenterol. 1998 33 593-596... 

Papotti M, Sambataro D, Marchesa P, Negro F. A combined hepatocellular/cholangiocellular carcinoma with sarcomatoid features. Liver. 1997 17 47-52. 

Kanamoto M, Yoshizumi T, Ik ami T, et al. Cholangiolocel-lular carcinoma containing hepatocellular carcinoma and cholangiocellular carcinoma, extremely rare tumor of the liver a case report. J Med Invest. 2008 55 161-165. 

Solitary fibrous tumor, synovial sarcoma, hepatic adenoma, neuroendocrine carcinoma, GIT adenocarcinomas, endometrioid carcinoma, cholangiocellular carcinoma... 

CD7 T-ALL and T-cell lymphomas CML, ALL, cholangiocellular carcinoma, pancreas carcinoma Thymocytes, mature T-cells and NK cells, pre-B cells, monocytes, early myeloid cells... 

Jakobs et al. [35] reported results on 39 treated patients (17 women, 22 men) that included colorectal cancer, metastatic breast cancer, hepatocellular carcinoma, neuroendocrine tumors, and a mixed group composed of metastatic pancreatic cancer, carcinoma of unknown primary, cholangiocellular carcinoma, thymus carcinoma, malignant melanoma, and choroid melanoma. In this mixed tumor group, two patients were lost for follow-up immediately after treatment. Two patients died before first follow-up 3 months after SIRT (one patient with choroid melanoma and one with carcinoma of unknown primary). However, at the first followup 3-4 months after SIRT, five of six patients presented with stable disease or partial response. The same applied for two of three patients at the followup at 5-6 months. Stable disease was noted in two of three patients at 10-11 months after SIRT. The median time to progression was 8 months (range 3-11 months), although two patients were lost and two died before first follow-up and were therefore not included in this analysis. The median survival was 2.2 months. 

---